Skincare coverage on Peptide News Digest tracks the cosmetic-peptide market — copper peptides (GHK-Cu), collagen-stimulating peptides, and the new wave of brand launches at conferences like in-cosmetics Global. The category is mostly unregulated in the US (cosmetic vs drug claims), which keeps the marketing claims loose and the clinical evidence loose with them.
Recent threads: SVEDA Bakuchiol skincare launches, Acetyl Heptapeptide-9 with colloidal-gold nanoparticle delivery, peptide-dendron systems for targeted skin penetration, MLPH peptide topicals, APN5 peptide programs, and Pelage Pharmaceuticals' PP405 hair-loss peptide.
Stories here cover product launches, brand moves, and the underlying chemistry. See #cosmetic-peptide for the chemistry class and #anti-aging for the broader marketing umbrella.
Moes Group, a California-based private and white-label skincare manufacturer, announced June 6 that it is producing blue copper peptide (GHK-Cu / copper tripeptide-1) skincare and haircare formulations for brand partners, with cosmetic-grade GHK-Cu in stock and production already running. The launch arrives as the topical GHK-Cu market broadens after FDA materials in May indicated that non-injectable GHK-Cu would return to Category 1 under the 503A process; the injectable form remains pending the second PCAC review scheduled before February 2027.
The copper-peptide (GHK-Cu, copper tripeptide-1) cosmetic category continued its 2026 surge through late May. Neurogan Health's 2% GHK-Cu body-care line documented a 32.8% reduction in wrinkle depth and 20-30% improvement in skin firmness in 12-week clinical testing. Auro Wellness, founded by peptide-delivery specialist Nayan Patel, anchors its copper-tripeptide serum on a proprietary delivery system. GHK-Cu is the fastest-growing peptide search term of 2026, with consumer interest spanning skin rejuvenation, hair loss, and systemic longevity. GHK-Cu activates over 4,000 human genes involved in collagen synthesis, anti-inflammation, and tissue remodeling. The cosmetic surge runs in parallel with the FDA's regulatory cycle: injectable GHK-Cu is on the docket for the February 2027 PCAC meeting alongside Melanotan II, LL-37, Dihexa, and PEG-MGF, while the topical cosmetic form remains in the lighter-regulated personal-care channel. The category illustrates the consumer end of the peptide landscape maturing alongside the therapeutic pipeline.
Neurogan Health expanded its product line with a topical 2% GHK-Cu copper peptide body care, supported by a 12-week clinical trial reporting 32.8% reduction in wrinkle depth and 20–30% improvement in skin firmness. The launch lands in a 2026 GHK-Cu market characterized by surging consumer interest — the peptide is the fastest-growing skincare ingredient by search volume, with patient interest spanning skin rejuvenation, hair loss, and systemic longevity. Topical GHK-Cu has the strongest evidence base among research peptides, going back decades on wound healing and collagen synthesis, and topical applications avoid the regulatory gray zone around the injectable formulation.
A systematic review and meta-analysis in The American Journal of Medicine analyzing collagen peptide supplements found significant improvements in skin elasticity, hydration, and wrinkles — but only in industry-funded and low-quality studies. High-quality studies and those without pharmaceutical funding showed no significant effect across all categories.
BASF launched NeoHelix Regenerate, a precision peptide developed with U.S. startup 3Helix that targets damaged collagen for renewal. A 56-day clinical study showed a 41% reduction in damaged collagen and 65% increase in hyaluronic acid levels. BASF also introduced SkinNexus Collag3n, a bio-identical recombinant Collagen III fragment produced via vegan yeast fermentation.
Pharmaceutical platform BoomRx debuted its copper peptide skincare line at the A4M Longevity SpringFest conference in West Palm Beach. The flagship product features Copper Tripeptide-1 (GHK-Cu), targeting med-spa and wellness practices already offering GLP-1, hormone, and hair loss treatments.
Dermatology Times Q&A explores advances in GHK-Cu delivery for skincare, discussing how the peptide complexes with copper in human plasma and new formulation approaches to improve topical efficacy.